Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
HPK1 inhibitor
NDI-101150 is an orally active, potent, and selective inhibitor of hematopoietic progenitor kinase 1 (HPK1). It enhances T cell activation and exhibits antitumor activity by promoting immune-mediated tumor suppression, making it a promising candidate for cancer immunotherapy research. -
HPK1/MAP4K1 inhibitor
PF-07265028 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1/MAP4K1) with potent cellular activity, demonstrated by a pSLP76 IC50 of 17 nM. It is a promising compound for cancer research, particularly in studies involving immune regulation and tumor immunotherapy. -
MAP4K4 Inhibitor
PF-06745013 is a selective inhibitor of MAP4K4, exhibiting an IC50 of 0.4 nM. This compound is distinguished by its lack of time-dependent inhibition risk for CYP3A4 and demonstrates non-ATP competitive activity. PF-06745013 has potential applications in the study of inflammatory diseases, including diabetes and cancer, making it a valuable tool in related research. -
HPK1 Inhibitor
HPK1-IN-69 is a potent inhibitor of HPK1 with an IC50 of 1.7 nM. This compound disrupts the HPK1-mediated T cell receptor signaling pathway, decreasing SLP76 phosphorylation and enhancing IL-2 release. In vivo studies demonstrate its anti-tumor efficacy in mouse models, making it a valuable reagent for investigating colorectal cancer and MC38 syngeneic tumors. -
TAK1/MAP4K2 Inhibitor
NG25 trihydrochloride is a potent dual inhibitor of TAK1 and MAP4K2, exhibiting IC50 values of 149 nM and 21.7 nM, respectively. This compound enhances the sensitivity of breast cancer cells to Doxorubicin, promoting apoptotic processes. NG25 trihydrochloride serves as a valuable tool for investigating therapeutic strategies in various cancer research applications. -
MAP4K4 Inhibitor
MAP4K4-IN-7 is a selective inhibitor of MAP4K4 that demonstrates moderate inhibitory activity against TNIK, MAP4K4, and MINK1, with pIC50 values of 6.8, 6.8, and 6.7, respectively. This compound can be utilized in research focused on cancer and neurological disorders, including conditions such as schizophrenia. Its ability to modulate MAP4K4 activity makes it a valuable tool for exploring therapeutic strategies in related pathologies. -
HPK1 Inhibitor
ZYF0033 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1), achieving an IC50 of less than 10 nM by inhibiting the phosphorylation of MBP protein. This compound enhances anti-cancer immune responses, leading to a reduction in serine 376 phosphorylation of SLP76. In preclinical studies with the 4T-1 syngeneic mouse model, ZYF0033 demonstrated significant tumor growth inhibition and increased intratumoral infiltration of dendritic cells, natural killer cells, and CD107a+CD8+ T cells, while decreasing infiltration of various PD-1+ and TIM-3+ CD8+ T cell subsets. -
HPK1 Inhibitor
HPK1-IN-3 is a potent and selective ATP-competitive inhibitor of hematopoietic progenitor kinase 1 (HPK1; MAP4K1), exhibiting an IC50 of 0.25 nM. The compound demonstrates significant IL-2 potency, with an EC50 of 108 nM in human peripheral blood mononuclear cells (PBMCs). This makes HPK1-IN-3 a valuable tool for investigating the role of HPK1 in immune modulation and cellular signaling pathways. Its targeted inhibition offers potential applications in the study of hematopoietic cell functions and autoimmune disorders. -
HPK1 Inhibitor
DS21150768 is a selective inhibitor of HPK1, a key regulator of T-cell activation. This compound enhances T-cell function and may exhibit potential anticancer effects by modulating immune responses. DS21150768 is suitable for research applications focused on cancer immunotherapy and T-cell biology. -
MAP4K4 Inhibitor
MAP4K4-IN-3 is a potent and selective inhibitor of MAP4K4, exhibiting an IC50 of 14.9 nM in kinase assays and 470 nM in cellular assays. This compound demonstrates significant antidiabetic activity, making it a valuable tool for research in diabetes and metabolic disorders. Its specific action on the MAP4K4 pathway allows for detailed investigation of its biological effects and potential therapeutic applications. -
MAP4K Inhibitor
Famlasertib is a potent inhibitor of MAP4K, specifically targeting HGK (MAP4K4), MLK3, and MLK1 with IC50 values of 0.3 nM, 23.7 nM, and 44.7 nM, respectively. This compound demonstrates neuroprotective and anti-inflammatory effects, making it a valuable tool in research focused on amyotrophic lateral sclerosis (ALS). Famlasertib's ability to penetrate the blood-brain barrier enhances its potential for exploring therapeutic interventions in neurodegenerative diseases. -
HPK1 Inhibitor
HPK1-IN-32 is a potent and selective inhibitor of HPK1, exhibiting an IC50 of 65 nM. This compound is valuable for investigating HPK1-related disorders and diseases, making it an essential tool for research applications targeting cellular signaling pathways associated with immune responses and inflammation. -
HPK1 Inhibitor
HPK1-IN-7 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1, MAP4K1) with an IC50 of 2.6 nM, demonstrating excellent selectivity among kinases. It exhibits some selectivity against IRAK4 and GLK, with IC50 values of 59 nM and 140 nM, respectively. This compound has shown significant efficacy in the MC38 syngeneic tumor model, particularly when used in combination with anti-PD1 therapy, highlighting its potential in immuno-oncology research. -
HPK1/GLKb Inhibitor
HPK1/GLK-IN-1 is an inhibitor targeting HPK1 and GLK, demonstrating potent inhibition of GLK with an IC50 value of 33 nM. This compound is primarily utilized in research focused on the modulation of HPK1/GLK signaling pathways, making it a valuable tool for studying animal pathogen infections and related biological mechanisms. Its specificity and potency provide researchers with an effective means to explore therapeutic interventions targeting these kinases. -
HPK1 Inhibitor
GNE-1858 is a highly potent inhibitor of hematopoietic progenitor kinase-1 (HPK1), acting through ATP-competitive mechanisms with IC50 values of 1.9 nM for wild-type HPK1 and 4.5 nM for the active mimetic mutant HPK1-SA. Its remarkable selectivity and efficacy make it an invaluable tool for studying HPK1-related pathways in cellular signaling. GNE-1858 has potential applications in cancer research and immunology, particularly in the modulation of T cell responses and hematopoiesis. -
MAP4K Inhibitor
GNE 220 hydrochloride is a potent and selective inhibitor of MAP4K4, exhibiting an IC50 of 7 nM. This compound demonstrates significant inhibitory activity against MAP4K4, making it a valuable tool for research focused on signaling pathways involved in cellular processes such as differentiation, proliferation, and apoptosis. GNE 220 is particularly relevant for studies investigating the role of MAP4K4 in various diseases, including cancer and inflammatory disorders. -
HPK1 Inhibitor
HPK1-IN-4 is a highly potent inhibitor of HPK1 (MAPK41), exhibiting an IC50 value of 0.061 nM. This compound serves as a valuable tool in preclinical immunological research, facilitating the study of HPK1's role in immune signaling pathways. Its specificity and efficacy make it an essential reagent for investigating therapeutic targets in immune-related disorders. -
HPK1 Inhibitor
HPK1-IN-34 is an inhibitor of Hematopoietic progenitor kinase 1 (HPK1), exhibiting an IC50 of less than 100 nM. This compound serves as a valuable tool in the study of HPK1's role in cellular signaling and immune response. Additionally, HPK1-IN-34 features a terminal alkyne group, enabling its application in click chemistry through copper-catalyzed azide-alkyne cycloaddition (CuAAc), facilitating the conjugation with azide-functionalized molecules for various biochemical studies. -
MAP4K4 Inhibitor
Pyrrolo[2,1-f][1,2,4]triazin-4-amine is an inhibitor of MAP4K4, demonstrating a Kd of 88 μM as assessed by surface plasmon resonance (SPR), with a ligand efficiency of 0.56. This compound is valuable for studies investigating the roles of MAP4K4 in cellular signaling and disease pathways. Its inhibitory properties make it suitable for biochemical assays and potential therapeutic research involving MAP4K4 modulation. -
HPK1 Inhibitor
HPK1-IN-19 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1), a critical regulator in various cellular processes, including immune responses and cell proliferation. This compound exhibits significant potential in modulating HPK1 activity, making it valuable for research in immunology and cancer biology. Its ability to impact signaling pathways may provide insights into therapeutic strategies for diseases involving dysregulated HPK1 function. -
MAP4K Inhibitor
HPK1-IN-8 is an allosteric inhibitor targeting the MAP4K family, specifically designed to stabilize the inactive conformation of full-length HPK1. This compound demonstrates selective inhibition of HPK1, which is implicated in various cellular signaling pathways. It is a valuable tool for research investigating the modulation of immune responses, cancer biology, and other conditions associated with dysregulated MAP4K signaling. -
TNIK/MAP4K4 Inhibitor
TNIK&MAP4K4-IN-1 is a potent dual inhibitor targeting TNIK and MAP4K4/HGK, demonstrating IC50 values of 1.29 nM and less than 10 nM, respectively, in human hepatic stellate cell line LX-2. This compound exhibits significant biological activity in inhibiting pathways associated with cancer and fibrotic processes. It serves as a valuable tool for researchers studying the roles of TNIK and MAP4K4 in cellular signaling and disease progression. -
HPK1 Inhibitor
(3S,4R)-GNE-6893 is a selective inhibitor of HPK1, an important regulator in immune signaling pathways. This compound exhibits potent and orally bioavailable inhibition, making it a valuable tool for exploring the roles of HPK1 in cancer biology. Its biological activity provides insights for research applications focused on cancer therapeutics and immune modulation. -
MAP4K Inhibitor
GNE-220 is a potent and selective inhibitor of MAP4K4, exhibiting an IC50 of 7 nM. This compound plays a crucial role in modulating MAPK signaling pathways, making it valuable for studying cell proliferation and apoptosis. GNE-220 is applicable in research focused on cancer biology and inflammatory diseases, where MAP4K4 is implicated in disease progression. -
HPK1 Inhibitor
HPK1-IN-15 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1), a member of the MAP4K family implicated in various signaling pathways. This compound is valuable for investigating the role of HPK1 in diseases such as cancer and for exploring potential therapeutic approaches to modulate HPK1 activity. Its specificity and potency make it an important tool in both basic research and drug development efforts targeting HPK1-related mechanisms. -
HPK1 Inhibitor
HPK1-IN-16 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1), a member of the MAP kinase kinase kinase kinase (MAP4K) family. By specifically targeting HPK1, this compound demonstrates potential in the study of various diseases linked to HPK1 activity, including cancer. HPK1-IN-16 is valuable for research applications focused on the modulation of HPK1-related pathways to better understand disease mechanisms and explore therapeutic interventions. -
HPK1 Inhibitor
HPK1-IN-13 is a selective inhibitor of HPK1, a serine/threonine protein kinase implicated in hematopoietic progenitor cell signaling. As a member of the MAP4K family of mammalian Ste-20-related kinases, HPK1 plays a crucial role in various cellular processes. HPK1-IN-13 is designed for research applications targeting HPK1-related diseases, offering potential insights into its role in health and disease states. -
HPK1 Inhibitor
HPK1-IN-12 is a potent inhibitor of HPK1, a serine/threonine protein kinase that is part of the MAP4K family of mammalian Ste-20-related protein kinases. This compound selectively targets HPK1 and demonstrates significant inhibitory effects, making it a valuable tool for studying HPK1-related diseases. Its application in research can contribute to the understanding of the molecular mechanisms underlying various pathologies involving HPK1 signaling pathways. -
HPK1 Inhibitor
HPK1-IN-17 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1), a member of the MAP kinase kinase kinase kinase (MAP4K) family. This compound is instrumental in investigating the role of HPK1 in various diseases, particularly in cancer, by modulating its activity. HPK1-IN-17 is valuable for research applications aimed at understanding HPK1's involvement in hematopoiesis and potential therapeutic interventions. -
HPK1 Inhibitor
HPK1-IN-14 is a selective inhibitor of HPK1, a serine/threonine protein kinase that is part of the MAP4K family and is found in hematopoietic progenitor cells. This compound exhibits significant potential for inhibiting HPK1 activity, making it a valuable tool for research into HPK1-related diseases and cellular signaling pathways. Researchers can utilize HPK1-IN-14 to investigate the roles of HPK1 in various biological processes and therapeutic contexts. -
HPK1 Inhibitor
HPK1-IN-11 is a potent inhibitor of HPK1, a serine/threonine protein kinase that is part of the MAP4K family of mammalian Ste-20-related protein kinases. This compound is valuable for investigating HPK1-related diseases and can facilitate research into the molecular mechanisms associated with these conditions. Its inhibitory properties make HPK1-IN-11 a critical tool for studying the role of HPK1 in various biological processes. -
HPK1 Inhibitor
HPK1-IN-10 is a potent inhibitor of the serine/threonine protein kinase HPK1, which is classified within the MAP4K family of mammalian Ste-20-related protein kinases. This compound demonstrates significant biological activity by modulating the signaling pathways associated with HPK1, making it a valuable tool for investigating HPK1-related diseases. Research applications include the study of immune responses and potential therapeutic interventions in related pathologies. -
HPK1 Inhibitor
HPK1-IN-18 is a potent and selective inhibitor of hematopoietic progenitor kinase 1 (HPK1), a member of the MAP kinase kinase kinase kinases (MAP4Ks) family. This compound demonstrates significant biological activity by modulating HPK1 signaling pathways, making it a valuable tool for research into cancer and other disorders associated with HPK1 activity. Its application can aid in elucidating the role of HPK1 in various biological processes and potential therapeutic interventions. -
HPK1 Inhibitor
HPK1-IN-31 is a potent hematopoietic progenitor kinase 1 (HPK1) inhibitor, exhibiting an IC50 value of 0.8 nM. This compound demonstrates significant anti-tumor activity, making it a valuable tool in cancer research. Its ability to modulate immune responses further enhances its potential applications in immunological studies. -
HPK1 Kinase Inhibitor
HPK1-IN-21 is a potent inhibitor of HPK1 kinase, exhibiting a Ki value of 0.8 nM. This compound demonstrates significant biological activity in modulating immune responses through inhibition of T-cell signaling pathways. HPK1-IN-21 is of particular interest for research applications in cancer immunotherapy and the study of autoimmune diseases. -
HPK1 Inhibitor
HDM2004 is a selective inhibitor of HPK1, demonstrating potent activity with an IC50 of 1.89 nM. This compound is orally bioavailable and effectively penetrates the blood-brain barrier, exhibiting notable anticancer activity against colon cancer. Additionally, HDM2004 shows synergistic effects when used in combination with anti-PD-L1 in syngeneic mouse models, making it a valuable tool for research into colon cancer therapies. -
HPK1 Inhibitor
HMC-B17 is a selective inhibitor of HPK1, exhibiting an IC50 of 1.39 nM. It enhances the secretion of IL-2 in Jurkat cells, with an EC50 of 11.56 nM, thereby potentiating the efficacy of anti-PD-L1 therapies. This compound is valuable for research into cancer mechanisms and immunotherapy strategies. -
HPK1 Inhibitor
HPK1-IN-36 is a potent inhibitor of HPK1, exhibiting an IC50 value of 0.5 nM. This compound selectively targets the HPK1 signaling pathway, which plays a crucial role in T cell activation and immune response regulation. HPK1-IN-36 is valuable for research applications aimed at understanding immune modulation and investigating potential therapies for autoimmune diseases and immune-related disorders. -
HPK1 Inhibitor
HPK1-IN-41 is a potent inhibitor of the HPK1 protein, exhibiting an IC50 value of 0.21 μM. This compound is instrumental in research focused on diseases linked to HPK1 activity, enabling studies on its role in various cellular processes and potential therapeutic interventions. Its utility in modulating HPK1 makes it a valuable tool for exploring targeted treatments in related pathologies. -
HPK1 Inhibitor
HPK1-IN-27 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1), a serine/threonine kinase within the MAP4K family. This compound modulates critical signaling pathways involved in cell proliferation and survival, making it a valuable tool for cancer research. Its ability to inhibit HPK1 activity contributes to investigations into the mechanistic roles of this kinase in tumorigenesis and potential therapeutic interventions. -
HPK1 Inhibitor
HPK1-IN-28 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1), which functions as a negative regulator in the activation of dendritic cells, T cells, and B cells. This compound enhances anti-tumor immunity, making it a valuable tool for research in immune-related diseases, particularly in tumor immunology. HPK1-IN-28 offers significant potential for investigating therapeutic strategies aimed at modulating immune responses. -
HPK1 Inhibitor
HPK1-IN-35 is a potent and selective inhibitor of HPK1, demonstrating an IC50 value of 3.5 nM. This compound effectively reduces the phosphorylation of SLP76 while promoting the secretion of interleukin-2 (IL-2). HPK1-IN-35 is particularly valuable for research in T cell activation and immune response modulation. -
HPK1 Inhibitor
HPK1-IN-49 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an IC50 value exceeding 100 nM. This compound is utilized in research to study the role of HPK1 in various cellular processes, including immune responses and signal transduction pathways. Its inhibition can provide insights into therapeutic strategies targeting HPK1-related diseases. -
HPK1 Inhibitor
HPK1-IN-29 is a selective inhibitor of hematopoietic progenitor kinase 1 (HPK1), a key negative regulator in the activation of dendritic cells, T cells, and B cells. By inhibiting HPK1, this compound enhances anti-tumor immune responses. HPK1-IN-29 is valuable for research into immune-related diseases, particularly in the context of cancer immunotherapy and tumor microenvironment modulation. -
HPK1 Inhibitor
HPK1-IN-52 is a potent inhibitor of hematopoietic progenitor kinase 1 (HPK1) with an IC50 value of 10.4 nM. This compound demonstrates significant anti-tumor activity, making it a valuable tool for studying the role of HPK1 in cancer biology. HPK1-IN-52 can be utilized in various research applications aimed at elucidating therapeutic strategies targeting HPK1-mediated pathways. -
HPK1 Inhibitor
HPK1-IN-9 is a potent inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1), a serine/threonine protein kinase associated with the MAP4K family of Ste-20-related protein kinases. This compound demonstrates significant biological activity in modulating HPK1 signaling pathways, making it a valuable tool for research into HPK1-related diseases. Researchers investigating the roles of HPK1 in various cellular processes may find HPK1-IN-9 particularly useful for elucidating its potential therapeutic implications. -
HPK1 Inhibitor
HPK1-IN-38 is a selective inhibitor of MAP4K1, also known as HPK1. This compound exhibits potent inhibition of HPK1's kinase activity, making it a valuable tool for studying HPK1-related biological processes. Its application is particularly relevant in research focused on immune response modulation and cancer biology, where HPK1 plays a critical role. -
HPK1 Inhibitor
HPK1-IN-20 is a specific inhibitor of hematopoietic progenitor kinase 1 (HPK1), which plays a critical role in immune signaling pathways. This compound demonstrates strong inhibition of HPK1 activity, which may enhance T cell activation and proliferation. It is suitable for research applications focused on immunological studies and potential therapeutic development for immune-related disorders. -
MAP4K1/HPK1 Inhibitor
HPK1-IN-37 is a selective inhibitor of MAP4K1/HPK1, demonstrating an IC50 of 3.7 nM. Its potent inhibitory activity makes it a valuable tool for investigating HPK1-related disorders, including various cancer types. Researchers can utilize HPK1-IN-37 to elucidate the role of HPK1 in signal transduction pathways and therapeutic interventions. -
MAP4K Inhibitor
BAY-405 is a potent MAP4K1 inhibitor that demonstrates nanomolar activity in both biochemical and cellular assays. Its effective inhibition of MAP4K1 has significant implications for research into pathways regulated by this kinase, making it a valuable tool for studying cellular processes such as proliferation, differentiation, and stress response. Additionally, BAY-405 is capable of achieving in vivo exposure following oral administration, enhancing its utility in preclinical studies.
